Merck’s Gardasil vaccine is now indicated for the prevention of genital warts (condyloma acuminata) caused by human papillomavirus (HPV) types 6 and 11 in boys and men 9 through 26 years of age. Gardasil is currently approved for use in girls and women 9 through 26 years of age for preventing cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18; precancerous lesions caused by types 6, 11, 16, and 18; and genital warts caused by types and 11.

Read the rest of this entry »

Pralatrexate (Folotyn, Allos) has been approved as the first agent to treat peripheral T-cell lymphoma (PTCL), often an aggressive type of non-Hodgkin’s lymphoma. Pralatrexate was designated as an orphan drug under the agency’s accelerated approval process.

Read the rest of this entry »